[Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Walter T; Jann H; Ansquer C; Deshayes E; Garcia-Carbonero R; Teule A et al. · 2026 · Lancet · Atlas ID WALTER2026

Phase 3 RCT (COMPETE, Lancet 2026) found [177Lu]Lu-edotreotide (PRRT) had superior progression-free survival vs everolimus (mTOR inhibitor) in advanced somatostatin receptor-positive GEP-NETs, establishing PRRT as preferred over mTOR inhibition in this setting.

At a glance

Evidence tierB Direct human evidence
Study type2 - Human Clinical Trial
Model systemHuman RCT
JournalLancet
Year2026
Peer reviewedYes
SourceDOI 10.1016/S0140-6736(26)00604-5

Abstract

Peptide receptor radionuclide and targeted therapy are both approved treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs), but clinical evidence for preferred sequencing is scarce. The COMPETE trial evaluated the efficacy and harms of peptide receptor radionuclide therapy ([Lu]Lu-edotreotide) versus targeted molecular therapy (everolimus) in patients with advanced, progressive, somatostatin receptor-positive GEP NETs.

Extracted findings

InterventionEverolimus (mTOR inhibitor) vs [177Lu]Lu-edotreotide
TargetmTORC1
ModelHuman
EffectPRRT superior to everolimus on PFS; mTOR inhibition inferior as first-line in GEP-NETs

Open in the Atlas explorer